[go: up one dir, main page]

AR059149A1 - Derivados de indoloquinoxalina con actividad anti viral - Google Patents

Derivados de indoloquinoxalina con actividad anti viral

Info

Publication number
AR059149A1
AR059149A1 ARP070100274A ARP070100274A AR059149A1 AR 059149 A1 AR059149 A1 AR 059149A1 AR P070100274 A ARP070100274 A AR P070100274A AR P070100274 A ARP070100274 A AR P070100274A AR 059149 A1 AR059149 A1 AR 059149A1
Authority
AR
Argentina
Prior art keywords
viral activity
anti viral
indoloquinoxaline
derivatives
indoloquinoxaline derivatives
Prior art date
Application number
ARP070100274A
Other languages
English (en)
Original Assignee
Vironova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vironova Ab filed Critical Vironova Ab
Publication of AR059149A1 publication Critical patent/AR059149A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de formula (1) en donde R1 se selecciona de H, F, CI, Br, CF3, alcoxi C1-6 y OH; R2 se selecciona de H y alquilo C1-6; n es 1-12; m es 0 o 1; Y se selecciona de CH2, NR3, (NR3R4)+X-, O y S; R3 y R4 son independientemente seleccionados de H y alquilo C1-4 y X se selecciona de aniones aceptables farmacéuticamente. Un método para preparar el compuesto, su uso como un fármaco, y un método de tratamiento.
ARP070100274A 2006-01-23 2007-01-22 Derivados de indoloquinoxalina con actividad anti viral AR059149A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0600134A SE529777C2 (sv) 2006-01-23 2006-01-23 Nya föreningar och användning därav

Publications (1)

Publication Number Publication Date
AR059149A1 true AR059149A1 (es) 2008-03-12

Family

ID=38287919

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100274A AR059149A1 (es) 2006-01-23 2007-01-22 Derivados de indoloquinoxalina con actividad anti viral

Country Status (24)

Country Link
US (1) US8076341B2 (es)
EP (1) EP1976853B1 (es)
JP (1) JP5190379B2 (es)
CN (1) CN101374845B (es)
AR (1) AR059149A1 (es)
AT (1) ATE506365T1 (es)
AU (1) AU2007206092B2 (es)
BR (1) BRPI0707203C1 (es)
CA (1) CA2637417C (es)
CY (1) CY1112596T1 (es)
DE (1) DE602007014008D1 (es)
DK (1) DK1976853T3 (es)
ES (1) ES2365423T3 (es)
HR (1) HRP20110534T1 (es)
IL (1) IL192820A (es)
NZ (1) NZ569840A (es)
PL (1) PL1976853T3 (es)
PT (1) PT1976853E (es)
RS (1) RS51933B (es)
RU (1) RU2437887C2 (es)
SE (1) SE529777C2 (es)
SI (1) SI1976853T1 (es)
WO (1) WO2007084073A1 (es)
ZA (1) ZA200806315B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE473977T1 (de) 2008-04-30 2010-07-15 Univ Duisburg Essen Indolä2,3-bü-, indenä1,2-bü- und indenä2,1- büpyridoä2,3-fü quinoxalin-3-carboxylsäuren und ester, verfahren zu ihrer herstellung und ihre verwendung als antivirus- und antitumormittel
EP2489354A1 (en) 2011-02-18 2012-08-22 Vironova AB Pharmaceutical formulation of B220 for topical treatment of herpes
CN105061432B (zh) * 2015-07-16 2017-09-29 河北大学 6H‑吲哚[2,3‑b]喹喔啉衍生物、药物组合物及其制备和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8600261D0 (sv) * 1986-01-21 1986-01-21 Lundblad Leif Indolokinoxaliner med substituenter i 6-position som innehaller cykliska grupper
SE8600260D0 (sv) * 1986-01-21 1986-01-21 Lundblad Leif Substituerade indolokinoxaliner
SE504862C2 (sv) * 1994-12-27 1997-05-20 Leif J I Lundblad Användning av vissa indolo-§2,3b¤-kinoxaliner för framställning av ett läkemedel för skydd av DNA i initieringsfasen och/eller promotionsfasen av karcinogenes och för förhindrande av oxidativ stress i patienter med sjukdomar relaterade till fria radikaler
SE527639C2 (sv) * 2004-06-17 2006-05-02 Oxypharma Ab Alkylsubstituerade indolokinoxaliner

Also Published As

Publication number Publication date
US8076341B2 (en) 2011-12-13
CN101374845A (zh) 2009-02-25
CN101374845B (zh) 2012-07-18
NZ569840A (en) 2011-06-30
JP2009523792A (ja) 2009-06-25
EP1976853B1 (en) 2011-04-20
SE529777C2 (sv) 2007-11-20
BRPI0707203B8 (pt) 2020-12-08
EP1976853A4 (en) 2010-04-21
IL192820A0 (en) 2009-02-11
SE0600134L (sv) 2007-07-24
PL1976853T3 (pl) 2011-09-30
BRPI0707203A2 (pt) 2011-04-26
CY1112596T1 (el) 2016-02-10
RU2437887C2 (ru) 2011-12-27
DK1976853T3 (da) 2011-08-08
US20090318458A1 (en) 2009-12-24
EP1976853A1 (en) 2008-10-08
HRP20110534T1 (hr) 2011-09-30
ES2365423T3 (es) 2011-10-04
SI1976853T1 (sl) 2011-09-30
BRPI0707203B1 (pt) 2020-11-10
CA2637417A1 (en) 2007-07-26
WO2007084073A1 (en) 2007-07-26
AU2007206092B2 (en) 2012-05-17
CA2637417C (en) 2014-08-05
IL192820A (en) 2012-08-30
DE602007014008D1 (de) 2011-06-01
JP5190379B2 (ja) 2013-04-24
ZA200806315B (en) 2010-04-28
ATE506365T1 (de) 2011-05-15
RU2008134509A (ru) 2010-02-27
RS51933B (sr) 2012-02-29
AU2007206092A1 (en) 2007-07-26
BRPI0707203C1 (pt) 2021-05-25
PT1976853E (pt) 2011-07-20

Similar Documents

Publication Publication Date Title
AR082985A1 (es) INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION
CR20200540A (es) DERIVADOS DE AMINA PARA EL CONTROL DE PLAGAS (Divisional 2019-0244)
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
PE20142456A1 (es) COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
PE20090060A1 (es) ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR
PE20151651A1 (es) Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20181519A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
ECSP099394A (es) Derivados de quinuclidinol como antogonistas de receptores muscarínicos
DE602007009839D1 (de) Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika
PE20141554A1 (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparacion, preparados farmaceuticos que los contienen, asi como su uso para la preparacion de medicamentos
JP2012512863A5 (es)
DE602007002915D1 (de) 2-benzoyl-imidazopyridin-derivate, herstellungsverfahren und ihre verwendung für therapeutika
MX343077B (es) Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos.
AR059149A1 (es) Derivados de indoloquinoxalina con actividad anti viral
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia
UY30673A1 (es) Derivados 6, 7 y 8 sustituidos del acido (3r)-5-oxo-2,3-dihidro-5h-tiazolo[3,2a]piridin-3-carboxilico, composiciones farmacéuticas conteniéndolos y aplicaciones.

Legal Events

Date Code Title Description
FC Refusal